Dogwood Therapeutics (DWTX) Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain Mar 18, 2025 08:45AM
Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain Mar 18, 2025 08:45AM
Dogwood Therapeutics (DWTX) Announces Conversion of Existing $19.5M in Debt to Equity Mar 12, 2025 08:31AM
Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward Mar 12, 2025 08:30AM
Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025 Jan 21, 2025 09:15AM


Nov 18, 2024 08:46AM Dogwood Therapeutics (DWTX) Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
Nov 18, 2024 08:45AM Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
Nov 7, 2024 07:05AM Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
Oct 31, 2024 09:15AM Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
Oct 30, 2024 09:16AM Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance
Oct 30, 2024 09:15AM Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement